Krystal Biotech: Investment Hypothesis Confirmed - The Platform Proof has been Established

In my previous analyses, I have already highlighted Krystal Biotech (KRYS) in detail. At that time, the focus was on the transformation from a research company to a profitable biotech player through the world's first topical gene therapy. However, the events of the first week of January 2026 require a reassessment of the situation. The investment thesis has transformed from a bet on a single product (Vyjuvek) to a true platform bet due to new clinical data. Here is the update you need to know. Status Quo: the basic hypothesis has been confirmed...